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Background: Homocysteinemia has been established as a risk factor for cardiovascular 
  disorders by the American Heart Association.1 Cerebrovascular accident (stroke) is presently 
ranked as one of the leading causes of morbidity and mortality worldwide. The aim of this study 
was to determine homocysteine and folate levels and some basic hematologic parameters in 
patients who sustain a cerebrovascular accident and those who do not.
Methodology: In total, 100 participants were recruited, comprising 40 clinically diagnosed 
stroke (hemorrhagic or thromboembolic) patients and 60 healthy control subjects. Plasma 
  homocysteine and folate levels were measured. Anticoagulated whole blood samples were 
evaluated for hemoglobin concentration (Hb), packed cell volume (PCV), white blood cell 
(WBC) count, and mean cell volume (MCV).
Results: The mean age of stroke patients was 62 ± 12 years and that of controls was 
55 ± 18 years (P = 0.1756). Mean plasma homocysteine levels for stroke patients and controls 
were 17.7 ± 4.4 µmol/L and 9.5 ± 2.4 µmol/L, respectively (P = 0.0000) and mean plasma 
folate levels for the groups were 6.5 ± 2.9 µg/dL and 4.0 ± 2.4 µg/dL (P = 0.0407). The MCV 
for stroke patients was significantly higher than that for controls (85 fl versus 82 fl, P = 0.04). 
Mean homocysteine levels correlated inversely with Hb and PCV (r = −0.08 and r = −0.122, 
respectively) and weakly with WBC (P = 0.125).
Conclusion: Homocysteinemia is a major predictor of cerebrovascular accident in the black 
Nigerian population.
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Introduction
Homocysteine is an amino acid in the blood. Epidemiologic studies have shown that 
elevated plasma homocysteine is related to a higher risk of coronary heart disease, 
stroke, and peripheral vascular disease.1 Other evidence suggests that homocysteine 
may have an effect on atherosclerosis by damaging the inner lining of arteries and 
promoting blood clots.2 Plasma homocysteine levels are strongly influenced by diet, 
as well as by genetic factors. The dietary components with the greatest effects are 
folic acid and vitamin B6 and B12. Folic acid and other B vitamins help break down 
homocysteine in the body.3 Several studies have found that higher blood levels of 
B vitamins are related, at least in part, to lower concentrations of homocysteine. Other 
recent evidence shows that low blood levels of folic acid are linked to a higher risk of 
fatal coronary heart disease and stroke. However, many studies still give conflicting 
reports of the association between plasma folate levels and increasing plasma homo-
cysteine levels. Most of the relevant published data are for Caucasians, and there is a Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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paucity of data for black populations, especially in Nigeria 
where nutritional deficiencies have been well documented 
in a large proportion of the population.4,5
With an upsurge in reported cases of cardiovascular 
disease and related mortality, it has become important 
to   determine plasma homocysteine levels as a possible 
predictive index of the risk of developing cardiovascular 
disorders.4
Homocysteine testing may be useful in checking the 
overall risk of heart disease for people with a strong personal 
or family history of heart disease but who do not have other 
risk factors that can be controlled, such as smoking or high 
blood pressure. Homocysteine testing may also be useful 
for people who have early heart disease but no known risk 
factors and for people who have had unexplained deep vein 
thrombosis or stroke.1
Materials and methods
Study location
The study was carried out at the Lagos University Teaching 
Hospital, Idi-Araba, and at the Lagos State University College 
of Medicine, Ikeja, both located in Lagos State, South West 
Nigeria. These centers are the peak tertiary referral health 
institutions in the state. The entire patient cohort seen with 
high blood pressure within a two-month period of data col-
lection and who had had a cerebrovascular accident (CVA) 
were selected for this study.
Study population and inclusion criteria
There were 100 participants in this study,   comprising 
40 clinically diagnosed stroke patients (all hospital admis-
sions) recruited over a period of two months and presenting 
primarily with blood pressure readings above 140/90 mmHg, 
hemiparesis, and loss of consciousness, and with no other 
documented history of chronic systemic disorders. Sixty 
clinically stable, age- and gender-matched control subjects 
were selected randomly from people coming to the hospi-
tal outpatient clinic for voluntary routine blood pressure 
check-up and urinalysis as a control group. Ethical approval 
for the study was obtained from the Ethical Committee of 
the Lagos University Teaching Hospital, and verbal consent 
was obtained from all participants in the study.
Sample collection and processing
Two venous nonfasting 4.5 mL blood samples were drawn 
from each subject, put into anticoagulant tubes contain-
ing sodium ethylenediaminetetraacetic acid (EDTA) and 
  heparin, and immediately placed in an ice pack cooler. 
Plasma obtained after centrifugation at 3000 rpm was stored. 
A homocysteine assay was done, using an enzyme-linked 
immunosorbent assay (ELISA, Diazyme Laboratories, 
La Jolla, CA). Folate levels were measured using high 
performance liquid chromatography (HPLC). Hematologic 
parameters, including hemoglobin (Hb), packed cell volume 
(PCV), white blood cell (WBC) count, and mean cell volume 
(MCV) were obtained from the sodium EDTA anticoagu-
lated blood sample using the automated Coulter cell counter 
(Advia 60, France).6
Homocysteine values were read off at a wavelength of 
380 nm (ultraviolet), and the actual concentration of plasma 
homocysteine was extrapolated from the standard curve. 
Folate values were read off the measured areas of the chro-
matograph, and actual concentration was estimated on the 
calibration curve obtained with the standards.
Statistical analysis
Data obtained were analyzed using the SPSS version 11 
(SPSS Inc., Chicago, IL). Quantitative variables were 
expressed as means ± standard deviation. Relationships were 
subjected to the student t-test and associations verified by 
Chi-square and Pearson correlation coefficient.
Results
The mean age of controls compared well with the mean 
age of the stroke patients (62 ± 12 years and 58 ± 18 years, 
respectively, P = 0.1756), as shown in Table 1. The mean 
value of homocysteine was 17.7 ± 4.4 µmol/L in the stroke 
patients, and this was significantly higher than for controls 
(9.5 ± 2.4 µmol/L, P = 0.0001). The mean value of serum 
folate was higher among the stroke patients than in controls 
(6.5 ± 2.9 and 4.0 ± 2.4, respectively, P = 0.0407).
There was no significant difference in the mean values 
of Hb, PCV , and WBC count for stroke patients and controls 
(P = 0.5144, P = 0.1784, and P = 0.3356, respectively). Mean 
values for homocysteine did not correlate well with Hb, 
PCV , or WBC count between stroke patients and controls 
(r = −0.08, −0.122, and 0.125, respectively). However, the 
Table 1 Demographic characteristics of study participants
Variables Study group  
F (%)
Control group  
F (%)
P value   
(t-test)
Males 28 (70) 40 (67)
Female 12 (30) 20 (33)
Total 40 (100) 60 (100)
Mean age 62 ± 12 years 58 ± 18 years 0.1756Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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MCV for stroke patients (85 fl) was higher than for controls 
(82 fl, P = 0.04).
High mean plasma homocysteine levels (.10 µmol/L) 
correlated well with the occurrence of stroke, with 88% of 
stroke patients having levels above 10 µmol/L (P = 0.00001). 
Mean folate levels were higher in the stroke patients. Table 4 
shows a higher association of stroke with a plasma folate 
level below 6 µg/L (P = 0.037).
Discussion
Of the 40 stroke patients who participated in our study, 70% 
(n = 28) were males and 30% (n = 12) were females. A previ-
ous study by Andrew et al2 showed no significant difference in 
gender prevalence of homocysteinemia. Mean homocysteine 
levels for both male and female participants in this study 
were 18.2 µmol/L and 17.1 µmol/L, respectively (P = 0.217). 
The majority of our stroke patients were elderly (mean age 
62 ± 12 years), corresponding well with the controls (mean 
age 58 ± 18 years, P = 0.1756). Mean values for plasma 
homocysteine in the stroke patients (17.7 ± 4.4 µmol/L) were 
significantly higher than that in controls (9.5 ± 2.4 µmol/L). 
This finding is consistent with results obtained by Nura et al3 
in Maiduguri, Northern Nigeria, who recorded a mean plasma 
homocysteine level of 20.8 µmol/L and 13.1 µmol/L for stroke 
patients and controls, respectively.
The literature is replete with information on the associa-
tion between high plasma homocysteine levels and stroke 
incidence. In a study of stroke in the elderly, Andrew 
et al2 concluded that nonfasting hyperhomocysteinemia 
is an independent risk factor for the incidence of stroke 
in this age group. Interestingly, their study failed to find 
this   association in Finnish men, an indication of possible 
geographical variations in the incidence of hyperhomo-
cysteinemia. In a study of adults with stroke in Gombe, 
Northern Nigeria, Glew et al4 showed no significant differ-
ence in plasma homocysteine levels of stroke patients and 
controls, although 85% of the stroke patients had plasma 
homocysteine levels above 10 µmol/L.4,5 Homocysteine 
induces oxidant damage of vascular endothelium, and thus 
increases the incidence of atherosclerosis and disturbance 
of normal hemostasis. Our study calculated an odds ratio of 
14 as shown in Table 3, an indication that a homocysteine 
level above 10 µmol/L is a significant risk factor for stroke 
(P = 0.0001). Mean plasma folate in the stroke patients was 
significantly higher than that in controls (6.5 ± 2.9 µg/L 
  versus 4.0 ± 2.4 µg/L, P = 0.0407). This finding is at variance 
with other studies in which lower plasma folate levels were 
found.6–9 In a study of homocysteine in pregnant women, 
Megahad and Thahor9 reported a negative correlation 
between plasma folate and plasma homocysteine levels.9 
However, the high level of plasma folate reported in this 
study may be iatrogenic, because virtually all the stroke 
patients were taking folate supplements. This position is 
further supported by the fact that the occurrence of stroke in 
our patients was significantly associated with plasma folate 
levels below 6 µg/L (P = 0.037, odds ratio 2.45). Moreover, 
the mean MCV of our stroke patients was significantly higher 
than that in the control group (85 ± 4.8 fl versus 82 ± 2.9 
fl, P = 0.04). This implies the existence of a subtle folate 
deficiency prior to the occurrence of stroke in these patients. 
However, no significant differences were observed between 
the mean values of Hb, PCV, and WBC count in our stroke 
patients and controls (0.1784 and 0.3356, respectively, 
P = 0.5144), and the mean values of homocysteine correlated 
inversely, albeit weakly, with the Hb and PCV of the study 
group (r = −0.08 and −0.122, respectively) and very weakly 
with the WBC of the study group (r = 0.125). This finding is 
consistent with a previous observation by Haddad et al.10
Table 2 Mean values (± SD) of measured hematological parameters, 
plasma homocysteine and folate in both control and study groups
Measured  
parameters
Study  
group
Control  
group
P value   
(t-test)
Hb (g/dL) 11.6 ± 2.3 12.1 ± 1.6 0.5144
PCV (%) 34.6 ± 7.1 36.6 ± 4.8 0.1784
WBC (cells × 109/L) 5893 ± 263.5 5142 ± 510 0.3356
MCV (fl) 85 ± 4.8 82 ± 2.9 0.04
Homocysteine (µmol/L) 17.7 ± 4.4 9.5 ± 2.4 0.0000
Folate (µg/L) 6.5 ± 2.9 4.0 ± 2.4 0.0407
Abbreviations: Hb, hemoglobin; PCV, packed cell volume; SD, standard deviation; 
WBC, white blood cell count; MCV, mean cell volume.
Table 3 Relationship between high homocysteine values and occurrence of stroke*
Groups Plasma homocysteine  
(.10 μmol/L) n (%)
Plasma homocysteine  
(,10 μmol/) n (%)
Total Chi-square P value
Stroke patients 35 (87.5) 5 (12.5) 40
Controls 20 (33.3) 40 (66.7) 60
Total 55 (100) 45 (100) 100 28.45 0.00001
Note: *Odds ratio = 14Journal of Blood Medicine
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Table 4 Association between high plasma folate and occurrence of stroke*
Group Plasma folate  
(.6 μg/L) n (%)
Plasma folate  
(,6 μg/L) n (%)
Total Chi-square P value
Stroke patients 18 (45.0) 22 (55.0) 40
Controls 15 (25) 45 (75) 60
Total 32 (100) 68 (100) 100 4.34 0.037
Note: *Odds ratio = 2.45
The low Hb and hematocrit values observed in both 
stroke patients and controls suggests the possibility of protein 
malnutrition, which has been correlated with hyperhomo-
cysteinemia in other research in African populations.11
Conclusion
The results of our study indicate that folate deficiency alone 
might not explain high levels of homocysteine in blacks 
with cardiovascular disorders, and future studies evaluat-
ing protein and calorie malnutrition in this population are 
necessary.
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